Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 815-825

  Zhao, Xing Cheng ^a   Dou, Guo Rui ^a   Wang, Li ^a   Liang, Liang ^a   Tian, Deng Mei ^a   Cao, Xiu Li ^a   Qin, Hong Yan ^a   Wang, Chun Mei ^a   Zhang, Ping ^a   Han, Hua ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HYBRID PROTEIN; NOTCH RECEPTOR; PROTIEN HD1R; TENIPOSIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; TISSUE NECROSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 84879667468     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13550     Document Type: Article

References (51)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Folkman J (2003). Fundamental concepts of the angiogenic process. Curr Mol Med 3, 643-651.
3. Chung AS, Lee J, and Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10, 505-514.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
5. Cabebe E and Wakelee H (2006). Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 42, 387-398.
6. Gerber HP and Ferrara N (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65, 671-680.
7. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, and Moore MJ (2006). Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12, 144-151.
8. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
9. Ebos JM, Lee CR, and Kerbel RS (2009). Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15, 5020-5025.
10. Jain RK, Duda DG, Clark JW, and Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3, 24-40.
11. Gridley T (2010). Notch signaling in the vasculature. Curr Top Dev Biol 92, 277-309.
12. Phng LK and Gerhardt H (2009). Angiogenesis: a team effort coordinated by notch. Dev Cell 16, 196-208.
13. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al. (2007). Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780.
14. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, and Wiegand SJ (2007). Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 104, 3219-3224.
15. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, et al. (2007). Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109, 4753-4760.
16. Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, and Eichmann A (2007). The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 104, 3225-3230.
17. Artavanis-Tsakonas S, Rand MD, and Lake RJ (1999). Notch signaling: cell fate control and signal integration in development. Science 284, 770-776.
18. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, and Wang CY (2005). Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8, 13-23.
19. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, et al. (2007). Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67, 11244-11253.
20. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, and Thurston G (2006). Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037.
21. Rehman AO and Wang CY (2006). Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 16, 293-300.
22. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, et al. (2006). Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087.
23. Dufraine J, Funahashi Y, and Kitajewski J (2008). Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27, 5132-5137.
24. Sainson RC and Harris AL (2007). Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 13, 389-395.
25. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, and Plowman GD (2010). Chronic DLL4 blockade induces vascular neoplasms. Nature 463, E6-E7.
26. Segarra M, Williams CK, Sierra Mde L, Bernardo M, McCormick PJ, Maric D, Regino C, Choyke P, and Tosato G (2008). Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112, 1904-1911.
27. Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS, and Duarte A (2008). Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 112, 1720-1729.
28. Williams CK, Li JL, Murga M, Harris AL, and Tosato G (2006). Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939.
29. Zhang JP, Qin HY, Wang L, Liang L, Zhao XC, Cai WX, Wei YN, Wang CM, and Han H (2011). Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization. Cancer Lett 309, 220-227.
30. Fortini ME and Bilder D (2009). Endocytic regulation of Notch signaling. Curr Opin Genet Dev 19, 323-328.
31. Seugnet L, Simpson P, and Haenlin M (1997). Requirement for dynamin during Notch signaling in Drosophila neurogenesis. Dev Biol 192, 585-598.
32. Avraamides CJ, Garmy-Susini B, and Varner JA (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8, 604-617.
33. Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, Bordignon C, Corti A, Rizzardi GP, and Musco G (2008). Structural basis for the interaction of isoDGR with the RGD-binding site of αvβ3 integrin. J Biol Chem 283, 19757-19768.
34. McDonald DM and Choyke PL (2003). Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725.
35. Caswell PT, Vadrevu S, and Norman JC (2009). Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 10, 843-853.
36. Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perezdel-Pulgar S, Carpenter PM, and Hughes CC (2003). Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 66, 102-112.
37. Dou GR, Wang YC, Hu XB, Hou LH, Wang CM, Xu JF, Wang YS, Liang YM, Yao LB, Yang AG, et al. (2008). RBP-J, the transcription factor down-stream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J 22, 1606-1617.
38. Regan JN and Majesky MW (2009). Building a vessel wall with notch signaling. Circ Res 104, 419-421.
39. Stewart KS, Zhou Z, Zweidler-McKay P, and Kleinerman ES (2011). Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood 117, 719-726.
40. Liu H, Kennard S, and Lilly B (2009). NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ Res 104, 466-475.
41. Jin S, Hansson EM, Tikka S, Lanner F, Sahlgren C, Farnebo F, Baumann M, Kalimo H, and Lendahl U (2008). Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ Res 102, 1483-1491.
42. Liu H, Zhang W, Kennard S, Caldwell RB, and Lilly B (2010). Notch3 is critical for proper angiogenesis and mural cell investment. Circ Res 107, 860-870.
43. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, et al. (2010). Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052-1057.
44. Dou GR, Wang L, Wang YS, and Han H (2012). Notch signaling in ocular vasculature development and diseases. Mol Med 18, 47-55.
45. Chiang A and Regillo CD (2011). Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 22, 199-204.
46. Carmeliet P and Jain RK (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10, 417-427.
47. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, and Jain RK (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91, 1071-1121.
48. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, et al. (2009). Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851.
49. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, and Adams RH (2009). The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137, 1124-1135.
50. Trifonova R, Small D, Kacer D, Kovalenko D, Kolev V, Mandinova A, Soldi R, Liaw L, Prudovsky I, and Maciag T (2004). The non-transmembrane form of Delta1, but not of Jagged1, induces normal migratory behavior accompanied by fibroblast growth factor receptor 1-dependent transformation. J Biol Chem 279, 13285-13288.
51. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, et al. (2011). DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 71, 6073-6083.